main content start

Pagina inicial

Continue Watching

Últimos vídeos

Últimos vídeos

Brightcove Home Latest Listing

Oncology

Oncology

Brightcove Cards Listing

Hematology

Hematology

Brightcove Cards Listing

Popular em MedEnrich

Popular em MedEnrich

Popular in Sem nome
  • Myelodysplastic Syndromes23m 43s

    Desenvolvimento e Atualizações na Biologia das Mielodisplasias

    Desenvolvimento e Atualizações na Biologia das Mielodisplasias (MDS)
    síndromes mielodisplásicas mds avanços na biologia terapias inovadoras epidemiologia da mds
  • Oncospecials15m 30s

    A Relevância dos Agentes TKI na era das imunoterapias para o tratamento do carcinoma de células Renais

    ONCOPLUS apresenta: vídeo-aula com Dr. Denis Jardim na patologia de carcinoma de células renais.
    oncologia ccr câncer renal tki sunitinibe
  • Mieloma múltiplo9m 20s

    Integrating Pomalidomide Based Regimens in Multiple Myeloma

    Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.
    pomalidomide-dexamethasone rrmm management progression-free survival combination therapies
  • Câncer de próstata6m 59s

    Managing Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)

    3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPC
    nmcrpc metastasis free survival spartan prosper & aramis clinical trial
  • Myelodysplastic Syndromes14m 13s

    ASH 2022 Update on Myelodysplastic Syndromes

    ASH 2022 - Update on Myelodysplastic Syndromes
    low risk mds venetoclax viale -a eln classification low dose lenalidomide tags: azacitidine
  • 3m 56s

    Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission

    There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.
    her2 positive mbc prolonged remission trastuzumab duration
  • Mieloma múltiplo17m 14s

    Tratamento do mieloma múltiplo

    Tratamento do mieloma multiplo_Dr Ederson Mattos
    mm mieloma múltiplo tratamento lenalidomida nccn ederson mattos
  • Acute Myeloid Leukaemia12m 22s

    EHA 2022 Updates : AML

    EHA Updates AML : QuANTUM phase 3 study showed significant overall survival in adults having FLT3-ITD+ acute myeloid leukaemia with  addition of quizartinib to standard induction and consolidation therapy alone.
    aml decitabine g-csf hypomethylating agents
  • 3m 56s

    Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission

    There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.
    her2 positive mbc prolonged remission trastuzumab duration
  • 11m 28s

    ESR1 Mutation in Hormone Receptor Positive Advanced Breast Cancer

    ESR1 mutation leads to ligand independent activation of estrogen receptor. ESR1 mutations were first described in 1997 & their role remain underestimated as initial research was focused on primary tumor wherein these mutations were absent.
    aromatase inhibitor resistance hr +ve mbc esr1 mutation fulvestrant

Webinar passado

Webinar Cards Listing

MedBytes

MedBytes

Medbytes Cards Listing
Hola, ¿puedo ayudar?
Suporte por bate-papoX
Equipe de suporte
Hola, ¿cómo puedo ayudarlo hoy?
Seleccione una de las siguientes opciones.

Buscar información

No puedo iniciar sesión o registrarse

compartilhar comentarios